The recent completion of the FDA's artificial intelligence-supported pilot project marks an important step in the modernization of scientific review processes. With the promise of speeding up evaluations and reducing repetitive tasks, the FDA plans to implement generative AI across the board by June 2025.

The new version of the MIR 7.3.1 form, published by the European Commission, brings relevant changes for manufacturers of medical and in vitro diagnostic devices. The updated form is mandatory in the context of Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR), and is aligned with post-market surveillance (PMS) requirements and the future use of the EUDAMED system. Manufacturers must ensure that they use the new MIR model, with updated fields, IMDRF coding, EMDN nomenclature and structured data such as UDI-DI, Basic UDI and SRN.

The new version of Swissmedic's guidance on GMP compliance verification of foreign manufacturers applies to all marketing authorization (MA) holders and their Responsible Persons (RP) in Switzerland.

The Swiss Federal Council recently approved a series of amendments to national legislation on medical devices, with a focus on strengthening patient safety, traceability through UDI and partial alignment with the European MDR Regulation. This legislative update aims to guarantee the continued safety and quality of medical devices marketed in Switzerland, even in the absence of an up-to-date Mutual Recognition Agreement with the European Union.

The new edition of the IMDRF Operating Procedures (Edition 13, 2025) clarifies the mechanisms for joining, developing and managing technical and regulatory documents in the medical devices sector. This document reinforces IMDRF's role in international harmonization, with a direct impact on the predictability of the rules applicable to manufacturers. The participation of regulatory authorities and industry stakeholders in these processes makes it possible to align technical requirements with global principles of compliance, safety and performance.

The new EUDAMED guide for legacy devices is an essential tool for medical device manufacturers who continue to operate under the previous MDD and AIMDD directives, but want to remain compliant during the transition period to Regulation (EU) 2017/745 (MDR). The document covers the assignment of EUDAMED DI and EUDAMED ID codes, the structured registration of legacy devices, the management of certificates and linking to already registered regulated devices. With practical guidelines and examples of accepted formats, this guide contributes to strengthening the traceability, compliance and regulatory security of legacy devices still on the European market.

The new EUDAMED user guide for Unique Identifier (UDI) devices is an indispensable reference for all medical device manufacturers who want to ensure compliance with the MDR and IVDR regulations. The document covers aspects such as registering Basic UDI-DI and UDI-DI, managing data in EUDAMED, connecting to legacy devices, and updating versions. It also includes crucial information on requirements for accessing the EUDAMED platform, user profiles, and the procedures for structured data submission. This guide is essential for ensuring an effective compliance strategy in the European regulatory context.

There's a symbol update you can't ignore. With the release of Amendment 1 to ISO 15223-1, the European Authorized Representative symbol is changing from EC REP to EU REP.

Team-NB 's official position paper on the implementation of the AI Act offers key guidance for manufacturers of medical devices with artificial intelligence. The document analyzes the integration between the AI Regulation and the requirements already established by the MDR and IVDR, underlining the classification of devices with AI as high-risk systems.

The new version of Team NB's good practice guide for submitting technical documentation under Regulation (EU) 2017/745 (MDR) provides clear guidance for medical device manufacturers. The document addresses the structuring of dossiers, the consistency of data, common mistakes to avoid and the importance of effective communication with Notified Bodies.

Implementing Decision (EU) 2025/681 introduces six new harmonized standards under the Medical Devices Regulation (MDR), directly impacting manufacturers of single-use medical gloves, sterile devices and ambulance patient transport equipment. Compliance with these standards allows presumption of conformity with the essential requirements of the MDR, facilitating CE marking and access to the European market. Smart MDR supports manufacturers in reviewing technical documentation, assessing regulatory impact and adapting processes to the new European legislation.

Smart MDR offers support via WhatsApp for manufacturers of medical devices, IVDs and medical device software looking for support with CE Marking and European regulations. Talk to an expert consultant and accelerate access to the European market with confidence.

With the entry into force of the IVDR, rapid antigen tests for COVID-19 are now classified as Class D devices, requiring assessment by a Notified Body.

AI in healthcare has transformative potential, but it also raises ethical and regulatory challenges. The WHO has published guidelines on the governance of AI, with a focus on large-scale multimodal models (LMMs). These systems can revolutionize medical diagnosis, scientific research and drug development, but it is essential to guarantee data security, transparency of algorithms and equity of access.

The FDA 's new guidance on the evaluation of gender-specific data in clinical studies with medical devices highlights the importance of including men and women in a representative way in trial samples. The analysis of gender-differentiated data makes it possible to identify possible variations in the efficacy and safety of medical devices, contributing to a more rigorous and inclusive evaluation.

The FDA has released the March 2025 edition of the "Study Data Technical Conformance Guide", an essential document for ensuring regulatory compliance in the submission of standardized data in clinical studies. The new guidelines affect processes such as INDs, NDAs, ANDAs and BLAs, ensuring that manufacturers follow the standards of the FDA Data Standards Catalog. Compliance with these rules is key to avoiding delays and guaranteeing acceptance of electronic submissions to CDER and CBER.

ANVISA 's latest report on the Potential Risk Monitoring and Intervention Pilot Project highlights a strategic, data-based approach to reducing health risks in priority health services such as surgical centers, ICUs and ILPIs.

Medical device manufacturer looking to expand into Portugal and the European Union?

Smart MDR is making it easier for you to enter the European market with an unmissable offer!

When you hire our regulatory support service for CE Marking, you get 1 YEAR of EC-REP FREE!

Why choose Smart MDR?

🔹 Specialists with over 20 years' experience in European regulation

🔹 Agile, simplified and unbureaucratic process

🔹 Complete support to ensure your compliance

Your international expansion has never been easier!

Book a free meeting and take advantage of this exclusive opportunity.

Contact us: services@smartmdr.com

The new edition of IMDRF-NCAR WG/N14 introduces clearer rules for Field Notifications of Corrective Action (NCARs), reinforcing the safety of medical devices.

The IMDRF has published a Playbook for the evaluation of Artificial Intelligence and Machine Learning (AI/ML) medical devices, addressing safety, efficacy and regulatory requirements. Global harmonization of these medical devices is essential to ensure transparency, reliability and compliance.